Navigation Links
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Date:2/27/2008

t from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that everolimus will be approved for any oncology indications. Nor can there be any guarantee that everolimus will achieve any particular levels of revenue in the future. In particular, management's expectations regarding everolimus could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, gastrointestinal and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG (NYSE:

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
3. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
4. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
5. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
6. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
7. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
10. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Cyberonics, Inc. (NASDAQ: CYBX ) today ... Quarterly highlights 1   Operating results ... first quarter of fiscal 2014, and other achievements, include: ... of 6.8%; , Strong international net sales of $13.2 ... , U.S. net product sales reached a new high ...
(Date:8/21/2014)... CHESTERBROOK, Pa. , Aug. 21, 2014 /PRNewswire/ ... AUXL ), a specialty biopharmaceutical company, today announced ... study of collagenase clostridium histolyticum (or CCH) for ... known as cellulite. In the Phase 2a trial, ... (0.48mg) and high (0.84mg)) showed an improvement in ...
(Date:8/20/2014)... , Aug. 20, 2014  The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kentucky blocked the sale of ...
Breaking Medicine Technology:Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... Goodwin Biotechnology, Inc. (GBI) and OncoMax, LLC, a ... cell line engineering and manufacturing of a monoclonal antibody ... will be engineered by GBI,s collaborative partner, and then ... producer and manufacture the monoclonal antibody for use and ...
... Eppendorf AG has licensed patents covering ... for use in their thermal cyclers, including US patent ... its Eppendorf Mastercycler® pro gradient, Mastercycler gradient and Mastercycler ... Hamburg, Germany, develops, produces and distributes instruments and consumables ...
Cached Medicine Technology:Goodwin Biotechnology and OncoMax, a Maxwell Biotech Portfolio Company, Announce a "Bench-to-Clinic" Collaboration for an Important Advance in Oncology 2Goodwin Biotechnology and OncoMax, a Maxwell Biotech Portfolio Company, Announce a "Bench-to-Clinic" Collaboration for an Important Advance in Oncology 3
(Date:8/21/2014)... Top10BestSEOHosting.com has compared many professional SEO hosting companies and ... most reliable suppliers for webmasters who want to buy ... in websites in recent years, and the new demand ... web hosting companies that offer a variety of different ... providing hosting solutions to thousands of business and personal ...
(Date:8/21/2014)... August 11: – Robin William’s suicide was ... hanging, likely due to long-term depression. , ... Vocal Profiling investigator, appeared on the Joyce Riley Power ... hoping to help people understand why he chose not ... were proposed in terms of BioAcoustic Biology: Using vocal ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The costs paid ... continue to rise, according to insurer data. The Quotes Pros ... in real time using its tools at http://quotespros.com . ... the company homepage connects with providers offering multiple coverage packages ... are promoted to the public are now easier to compare ...
(Date:8/21/2014)... August 21, 2014 Today, Zane Benefits, ... on the premium tax credits in 2015. , According ... As part of the Affordable Care Act (ACA), premium ... purchase individual health insurance through the Health Insurance Marketplaces. ... eligibility and the amount of the tax credits, updated ...
(Date:8/21/2014)... in the coronary arteries of chronic kidney disease patients ... according to a new study in the Journal ... ). Researchers at the Johns Hopkins Bloomberg School of ... commonly used measures of subclinical atherosclerosis in predicting the ... , Approximately 50 percent of all patients with chronic ...
Breaking Medicine News(10 mins):Health News:Best SEO Hosting Suppliers in the Global Market Recommended by Top10BestSEOHosting.com 2Health News:Robin Williams: What he could not bear to face 2Health News:Robin Williams: What he could not bear to face 3Health News:Dental Insurance Now Quoted for Families Online at Insurer Portal 2Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2
... Sept. 12 GSI Securitization,Inc. (Pink Sheets: GSIEF) ... "GSI is engaged in a,project with nine separate ... and funding for healthcare accounts receivable. This is ... for funding of receivables in the,$2-trillion+ healthcare market. ...
... If you,re one of the,millions of Texans who ... your handkerchief: Allergy researchers at Presbyterian Hospital of,Dallas say ... decades. "The unusually wet weather this summer means ... for lots of people," said Gary Gross, MD, an,allergist ...
... 2007) -- The University of South Floridas global health ... AIDS has been strengthened with a $1.36-million research training ... USF Health received the five-year grant Sept. 11 from ... training program focused on the biomedical, behavioral, cultural and ...
... Sept. 12 Navitas Cancer Rehabilitation Centers,of ... providing integrated and,comprehensive cancer rehabilitation services, is ... new center in Albuquerque, New Mexico. The ... New Mexico Oncology,Hematology Consultants, Ltd., (NMOHC) the ...
... aid children in crucial days after trauma, developers say ... now allows doctors to monitor blood flow through the ... death in children with head injuries. , Brain trauma ... States. Almost 475,000 children suffer brain injuries annually, according ...
... depends on the steady work of a vital gene that ... School cancer geneticists have found. Their research reveals an ... system, and opens novel strategies for targeting the gene, which ... , We have identified a new pathway that is essential ...
Cached Medicine News:Health News:Allergists at Presbyterian Hospital of Dallas Say This Year's Fall Allergy Season Could be Worst in Decades 2Health News:Global Health Project targets reducing AIDS among India's adolescents 2Health News:Navitas Opens New Cancer Rehabilitation Center in Albuquerque in Conjunction With New Mexico Cancer Centers 2Health News:Navitas Opens New Cancer Rehabilitation Center in Albuquerque in Conjunction With New Mexico Cancer Centers 3Health News:Imaging Software Helps Track, Treat Injured Brains 2Health News:Unique role for blood formation gene identified 2
... Portex® Thermovent® T helps provide protection to the ... small and extremely lightweight making it ideal for ... a high rate of heat and moisture recovery, ... ,All HMEs and filters have ISO standard ...
... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
... The Ulti-Mist™ HME product line has the ... pediatrics to adults and from intubated patients ... superior humidification for both anesthesia and critical ... HME/Filters provide maximum protection for patients and ...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Medicine Products: